BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Falvey JD, Hoskin T, Meijer B, Ashcroft A, Walmsley R, Day AS, Gearry RB. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis 2015;21:824-31. [PMID: 25738372 DOI: 10.1097/MIB.0000000000000341] [Cited by in Crossref: 99] [Cited by in F6Publishing: 72] [Article Influence: 12.4] [Reference Citation Analysis]
Number Citing Articles
1 Savelkoul EHJ, Thomas PWA, Derikx LAAP, den Broeder N, Römkens TEH, Hoentjen F. Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis. Inflamm Bowel Dis 2022:izac200. [PMID: 36318229 DOI: 10.1093/ibd/izac200] [Reference Citation Analysis]
2 Chirra P, Sharma A, Bera K, Cohn HM, Kurowski JA, Amann K, Rivero MJ, Madabhushi A, Lu C, Paspulati R, Stein SL, Katz JA, Viswanath SE, Dave M. Integrating Radiomics With Clinicoradiological Scoring Can Predict High-Risk Patients Who Need Surgery in Crohn's Disease: A Pilot Study. Inflamm Bowel Dis 2022:izac211. [PMID: 36250776 DOI: 10.1093/ibd/izac211] [Reference Citation Analysis]
3 Breugelmans T, Arras W, Boen LE, Borms E, Kamperdijk L, de Man J, van de Vijver E, van Gils A, de Winter BY, Moes N, Smet A. Aberrant Mucin Expression Profiles Associate With Pediatric Inflammatory Bowel Disease Presentation and Activity. Inflamm Bowel Dis 2022:izac217. [PMID: 36239641 DOI: 10.1093/ibd/izac217] [Reference Citation Analysis]
4 Gordon BL, Galati JS, Yang S, Longman RS, Lukin D, Scherl EJ, Battat R. Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease. World J Gastroenterol 2022; 28(33): 4834-4845 [DOI: 10.3748/wjg.v28.i33.4834] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Pandey A, Achrafie L, Kodjamanova P, Tencer T, Kumar J. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes. Curr Med Res Opin 2022;38:1531-41. [PMID: 35608153 DOI: 10.1080/03007995.2022.2081453] [Reference Citation Analysis]
6 Swaminathan A, Borichevsky GM, Edwards TS, Hirschfeld E, Mules TC, Frampton CMA, Day AS, Hampton MB, Kettle AJ, Gearry RB. Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease. J Crohns Colitis 2022;16:1862-73. [PMID: 35803583 DOI: 10.1093/ecco-jcc/jjac098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Peng Z, Yi J, Liu X. A Low-FODMAP Diet Provides Benefits for Functional Gastrointestinal Symptoms but Not for Improving Stool Consistency and Mucosal Inflammation in IBD: A Systematic Review and Meta-Analysis. Nutrients 2022;14:2072. [DOI: 10.3390/nu14102072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chirra P, Muchhala A, Amann K, Krishnan K, Kurowski J, Viswanath SE. Identifying radiomic features associated with disease activity, patient outcomes, and serum phenotypes in pediatric Crohn's disease via MRI. Medical Imaging 2022: Image-Guided Procedures, Robotic Interventions, and Modeling 2022. [DOI: 10.1117/12.2613599] [Reference Citation Analysis]
9 Kishi M, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol 2022. [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y] [Reference Citation Analysis]
10 Vernia F, Viscido A, Di Ruscio M, Stefanelli G, Valvano M, Latella G. Fecal Lactoferrin and Other Putative Fecal Biomarkers in Crohn's Disease: Do They Still Have a Potential Clinical Role? Digestion 2021;102:833-44. [PMID: 34518458 DOI: 10.1159/000518419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Witges K, Sexton K, Graff LA, Targownik LE, Lix LM, Haviva C, Stone J, Shafer LA, Vagianos K, Bernstein CN. What Is a Flare? The Manitoba Living With IBD Study. Inflamm Bowel Dis 2022;28:862-9. [PMID: 34347048 DOI: 10.1093/ibd/izab192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Gong W, Guo K, Zheng T, Xie H, Li W, Li M, Hong Z, Ren H, Gu G, Wang G, Wu X, Ren J. JINLING (Judicious INdex of Luminal INflammation Grade) score, an effective indicator to assess inflammation severity in Crohn's disease. Eur J Gastroenterol Hepatol 2021;33:1049-54. [PMID: 33136728 DOI: 10.1097/MEG.0000000000001979] [Reference Citation Analysis]
13 Zhang M, Zhang H, Zhu Q, Bai X, Zhou Q, Ruan G, Li W, Ma L, Xiao M, Yang H, Qian J. Bowel ultrasound enhances predictive value based on clinical indicators: a scoring system for moderate-to-severe endoscopic activities in patients with ulcerative colitis. Therap Adv Gastroenterol 2021;14:17562848211030050. [PMID: 34345250 DOI: 10.1177/17562848211030050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Moses J, Sandberg K, Winberry G, Riera D, DeLozier S, Gupta SK, Reilly N, Park KT, Picoraro J. Clinical Practice Survey of Repeat Endoscopy in Pediatric Inflammatory Bowel Disease in North America. J Pediatr Gastroenterol Nutr 2021;73:61-6. [PMID: 33633082 DOI: 10.1097/MPG.0000000000003100] [Reference Citation Analysis]
15 Bromke MA, Neubauer K, Kempiński R, Krzystek-Korpacka M. Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis. J Clin Med 2021;10:2203. [PMID: 34069684 DOI: 10.3390/jcm10102203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
16 Gubatan J, Levitte S, Patel A, Balabanis T, Wei MT, Sinha SR. Artificial intelligence applications in inflammatory bowel disease: Emerging technologies and future directions. World J Gastroenterol 2021; 27(17): 1920-1935 [PMID: 34007130 DOI: 10.3748/wjg.v27.i17.1920] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 32] [Article Influence: 17.5] [Reference Citation Analysis]
17 Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T, Shiotani A, Hirai F, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J Gastroenterol 2021;56:560-9. [PMID: 33942166 DOI: 10.1007/s00535-021-01793-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
18 Sarbagili-Shabat C, Weiner D, Wardi J, Abramas L, Yaakov M, Levine A. Moderate-to-severe Endoscopic Inflammation is Frequent After Clinical Remission in Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2021;72:569-73. [PMID: 33346576 DOI: 10.1097/MPG.0000000000003018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Tai FWD, Ellul P, Elosua A, Fernandez-Urien I, Tontini GE, Elli L, Eliakim R, Kopylov U, Koo S, Parker C, Panter S, Sidhu R, McAlindon M. Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn's disease: A European multicentre observational cohort study.United European Gastroenterol J. 2021;9:248-255. [PMID: 32741315 DOI: 10.1177/2050640620948664] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
20 Byrd KM, Gulati AS. The "Gum-Gut" Axis in Inflammatory Bowel Diseases: A Hypothesis-Driven Review of Associations and Advances. Front Immunol 2021;12:620124. [PMID: 33679761 DOI: 10.3389/fimmu.2021.620124] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
21 Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MDLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. Gastroenterología y Hepatología (English Edition) 2021;44:87-95. [DOI: 10.1016/j.gastre.2020.04.010] [Reference Citation Analysis]
22 Fischer S, Cohnen S, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, Zundler S, Rath T, Krebs S, Dörje F, Uter W, Nagore D, Meyer S, Neurath MF, Atreya R. Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Therap Adv Gastroenterol 2021;14:1756284820982802. [PMID: 33505519 DOI: 10.1177/1756284820982802] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
23 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
24 Axelrad JE, Sachs MC, Ludvigsson JF, Olén O; SWIBREG Study Group. A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data. Clin Epidemiol 2020;12:1059-72. [PMID: 33116900 DOI: 10.2147/CLEP.S265404] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Honig G, Heller C, Hurtado-Lorenzo A. Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2020;26:1451-62. [PMID: 32812036 DOI: 10.1093/ibd/izaa210] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
26 Krzystek-Korpacka M, Kempiński R, Bromke M, Neubauer K. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics (Basel) 2020;10:E367. [PMID: 32498475 DOI: 10.3390/diagnostics10060367] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
27 Nardone OM, Shivaji UN, Ferruzza V, Ghosh S, Iacucci M. Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. Inflamm Bowel Dis 2020;26:961-9. [PMID: 31587036 DOI: 10.1093/ibd/izz226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
28 Principi M, Contaldo A, Bianchi FP, Losurdo G, Iannone A, Ierardi E, Tafuri S, Di Leo A, IBD Endoscopy Team Work IBD Endoscopy Team Work. Inter-Observer Agreement of a New Endoscopic Score for Ulcerative Colitis Activity: Preliminary Experience. Diagnostics 2020;10:213. [DOI: 10.3390/diagnostics10040213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Piotrowicz G, Klufczyńska A, Banaszkiewicz P, Dorosz Ł, Rydzewska G. Assessment of the usefulness of imaging studies and biomarkers in the activity of Crohn's disease. Prz Gastroenterol 2021;16:15-22. [PMID: 33986883 DOI: 10.5114/pg.2020.93539] [Reference Citation Analysis]
30 Schoepfer A, Vavricka SR, Brüngger B, Blozik E, Bähler C. Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland. Eur J Gastroenterol Hepatol 2020;32:350-7. [PMID: 31834046 DOI: 10.1097/MEG.0000000000001616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Marinelli C, Zingone F, Inferrera M, Lorenzon G, Rigo A, Facchin S, Caccaro R, D'Incà R, Savarino EV. Factors associated with disability in patients with ulcerative colitis: A cross-sectional study. J Dig Dis 2020;21:81-7. [PMID: 31859432 DOI: 10.1111/1751-2980.12837] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
32 Marinelli C, Savarino EV, Marsilio I, Lorenzon G, Gavaruzzi T, D'Incà R, Zingone F. Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors - A cross-sectional study. Sci Rep 2020;10:507. [PMID: 31949257 DOI: 10.1038/s41598-020-57460-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
33 Rowan CR, Cullen G, Mulcahy HE, Sheridan J, Moss AC, Ryan EJ, Doherty GA. DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a Simple Method to Quantify Inflammatory Burden in Ulcerative Colitis. J Crohns Colitis 2019;13:1365-71. [PMID: 30911757 DOI: 10.1093/ecco-jcc/jjz067] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
34 Malham M, Carlsen K, Riis L, Paerregaard A, Vind I, Fenger M, Wewer V. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative Colitis. Scand J Gastroenterol 2019;54:1214-9. [PMID: 31526273 DOI: 10.1080/00365521.2019.1665097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
35 Adler SN, González Lama Y, Matallana Royo V, Suárez Ferrer C, Schwartz A, Bar-Gil Shitrit A. Comparison of small-bowel colon capsule endoscopy system to conventional colonoscopy for the evaluation of ulcerative colitis activity. Endosc Int Open 2019;7:E1253-61. [PMID: 31579707 DOI: 10.1055/a-0982-2786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Galazzo G, Tedjo DI, Wintjens DSJ, Savelkoul PHM, Masclee AAM, Bodelier AGL, Pierik MJ, Jonkers DMAE, Penders J. Faecal Microbiota Dynamics and their Relation to Disease Course in Crohn's Disease. J Crohns Colitis 2019;13:1273-82. [PMID: 30810207 DOI: 10.1093/ecco-jcc/jjz049] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
37 Marinelli C, Savarino E, Inferrera M, Lorenzon G, Rigo A, Ghisa M, Facchin S, D'Incà R, Zingone F. Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients. Gastroenterol Res Pract 2019;2019:5354320. [PMID: 31531015 DOI: 10.1155/2019/5354320] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
38 Sexton KA, Walker JR, Targownik LE, Graff LA, Haviva C, Beatie BE, Petty SK, Bernstein MT, Singh H, Miller N, Bernstein CN. The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application. Inflamm Bowel Dis 2019;25:1277-90. [PMID: 30918969 DOI: 10.1093/ibd/izz038] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
39 Protopapas AA, Vradelis S, Karampitsakos T, Steiropoulos P, Chatzimichael A, Paraskakis E. Elevated Levels of Alveolar Nitric Oxide May Indicate Presence of Small Airway Inflammation in Patients with Inflammatory Bowel Disease. Lung 2019;197:663-70. [PMID: 31317255 DOI: 10.1007/s00408-019-00253-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
40 Long MD. A Novel Index to Measure Patient-Reported Outcomes in Clinical Practice and Research: The Inflammatory Bowel Disease Symptom Inventory-Ready for Prime Time? Inflamm Bowel Dis 2019;25:1291-2. [PMID: 31219158 DOI: 10.1093/ibd/izz041] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Braun T, Di Segni A, BenShoshan M, Neuman S, Levhar N, Bubis M, Picard O, Sosnovski K, Efroni G, Farage Barhom S, Glick Saar E, Lahad A, Weiss B, Yablecovitch D, Lahat A, Eliakim R, Kopylov U, Ben-Horin S, Haberman Y. Individualized Dynamics in the Gut Microbiota Precede Crohn's Disease Flares. Am J Gastroenterol 2019;114:1142-51. [PMID: 30741738 DOI: 10.14309/ajg.0000000000000136] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
42 Bitar H. More pictures: better clarity or more artifact. Gastrointest Endosc 2019;90:168. [PMID: 31228980 DOI: 10.1016/j.gie.2019.01.024] [Reference Citation Analysis]
43 Day AS, Ho SSC, Leach ST. Letter to the Editor Re: Serum Calprotectin in Adolescents With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;68:e109. [PMID: 30908387 DOI: 10.1097/MPG.0000000000002345] [Reference Citation Analysis]
44 Restellini S, Chao CY, Martel M, Barkun A, Kherad O, Seidman E, Wild G, Bitton A, Afif W, Bessissow T, Lakatos PL. Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review. Clin Gastroenterol Hepatol 2019;17:1265-1275.e8. [PMID: 30583048 DOI: 10.1016/j.cgh.2018.12.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
45 Tajra JB, Calegaro JU, de Paula AP, Bachour D, Silveira D, Lozi M, Cavalcanti H. Correlation and concordance measures between clinical, endoscopic and histological scores activity in Crohn's disease under treatment. Scand J Gastroenterol 2019;54:441-5. [PMID: 30939952 DOI: 10.1080/00365521.2019.1596305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
46 Essmann J, Keil C, Unruh O, Otte A, Manns MP, Bachmann O. Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease. Eur J Gastroenterol Hepatol 2019;31:99-108. [PMID: 30212402 DOI: 10.1097/MEG.0000000000001262] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
47 Smits LJT, van Esch AAJ, Derikx LAAP, Boshuizen R, de Jong DJ, Drenth JPH, Hoentjen F. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study. Inflamm Bowel Dis 2019;25:172-9. [PMID: 29947795 DOI: 10.1093/ibd/izy227] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
48 Ziv-Baran T, Hussey S, Sladek M, Amil Dias J, Martin de Carpi J, Miele E, Veres G, Lionetti P, Koletzko S, Nuti F, Paerregaard A, Kolho KL, Russell RK, Shaoul R, Weiner D, Sigall Boneh R, Escher J, Finnby L, Turner D, Levine A. Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn's disease. Aliment Pharmacol Ther 2018;48:1242-50. [PMID: 30450578 DOI: 10.1111/apt.15016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
49 Melmed GY, Dubinsky MC, Rubin DT, Fleisher M, Pasha SF, Sakuraba A, Tiongco F, Shafran I, Fernandez-Urien I, Rosa B, Papageorgiou NP, Leighton JA. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study. Gastrointest Endosc 2018;88:947-955.e2. [PMID: 30086261 DOI: 10.1016/j.gie.2018.07.035] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
50 Iwamoto F, Matsuoka K, Motobayashi M, Takenaka K, Kuno T, Tanaka K, Tsukui Y, Kobayashi S, Yoshida T, Fujii T, Saito E, Yamaguchi T, Nagahori M, Sato T, Ohtsuka K, Enomoto N, Watanabe M. Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy. J Gastroenterol Hepatol 2018;33:1984-9. [PMID: 29889986 DOI: 10.1111/jgh.14310] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
51 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 188] [Cited by in F6Publishing: 157] [Article Influence: 37.6] [Reference Citation Analysis]
52 Bots S, Nylund K, Löwenberg M, Gecse K, Gilja OH, D'Haens G. Ultrasound for Assessing Disease Activity in IBD Patients: A Systematic Review of Activity Scores. J Crohns Colitis 2018;12:920-9. [PMID: 29684200 DOI: 10.1093/ecco-jcc/jjy048] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 11.8] [Reference Citation Analysis]
53 Wall CL, Gearry RB, Day AS. Treatment of Active Crohn's Disease with Exclusive and Partial Enteral Nutrition: A Pilot Study in Adults. Inflamm Intest Dis 2018;2:219-27. [PMID: 30221149 DOI: 10.1159/000489630] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
54 Schulze H, Esters P, Hartmann F, Stein J, Christ C, Zorn M, Dignass A. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. Scand J Gastroenterol 2018;53:670-6. [PMID: 29560811 DOI: 10.1080/00365521.2018.1452974] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
55 de Vries SAG, Tan CXW, Bouma G, Forouzanfar T, Brand HS, de Boer NK. Salivary Function and Oral Health Problems in Crohn's Disease Patients. Inflamm Bowel Dis 2018;24:1361-7. [PMID: 29718221 DOI: 10.1093/ibd/izy017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
56 Doherty MK, Ding T, Koumpouras C, Telesco SE, Monast C, Das A, Brodmerkel C, Schloss PD. Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients. mBio 2018;9:e02120-17. [PMID: 29535202 DOI: 10.1128/mBio.02120-17] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 14.0] [Reference Citation Analysis]
57 Piotrowicz G, Klufczyńska A, Kowerzanow J, Banaszkiewicz, P, Rydzewska G. Crohn’s disease activity evaluation based on imaging studies and biomarkers. GHOA 2018;9. [DOI: 10.15406/ghoa.2018.09.00292] [Reference Citation Analysis]
58 Moreau B, Clement P, Theoret Y, Seidman EG. Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD. Therap Adv Gastroenterol 2017;10:819-27. [PMID: 29147133 DOI: 10.1177/1756283X17733657] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
59 Andersson E, Bergemalm D, Kruse R, Neumann G, D'Amato M, Repsilber D, Halfvarson J. Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles. PLoS One 2017;12:e0186142. [PMID: 28982144 DOI: 10.1371/journal.pone.0186142] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
60 Julsgaard M, Hvas CL, Gearry RB, Vestergaard T, Fallingborg J, Svenningsen L, Kjeldsen J, Sparrow MP, Wildt S, Kelsen J, Bell SJ. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1240-6. [PMID: 28498159 DOI: 10.1097/MIB.0000000000001136] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
61 Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR, Irving PM. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther 2017;46:150-61. [PMID: 28481014 DOI: 10.1111/apt.14124] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
62 Kalappurayil NB, Thomas J, Mankuni B, Thomas V. Assessment of Disease Severity and Role of Cytomegalo Virus Infection in Patients with Ulcerative Colitis. J Clin Diagn Res 2017;11:EC07-11. [PMID: 28511386 DOI: 10.7860/JCDR/2017/22816.9332] [Reference Citation Analysis]
63 de Jong M, van der Meulen-de Jong A, Romberg-Camps M, Degens J, Becx M, Markus T, Tomlow H, Cilissen M, Ipenburg N, Verwey M, Colautti-Duijsens L, Hameeteman W, Masclee A, Jonkers D, Pierik M. Development and Feasibility Study of a Telemedicine Tool for All Patients with IBD: MyIBDcoach. Inflamm Bowel Dis 2017;23:485-93. [PMID: 28267047 DOI: 10.1097/MIB.0000000000001034] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
64 Sexton KA, Walker JR, Graff LA, Bernstein MT, Beatie B, Miller N, Sargent M, Targownik LE. Evidence of Bidirectional Associations Between Perceived Stress and Symptom Activity: A Prospective Longitudinal Investigation in Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:473-83. [PMID: 28221251 DOI: 10.1097/MIB.0000000000001040] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
65 Louis E, Van Kemseke C, Reenaers C. Objective Assessment of Clinical Disease Activity. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_23] [Reference Citation Analysis]
66 Shinzaki S, Matsuoka K, Iijima H, Mizuno S, Serada S, Fujimoto M, Arai N, Koyama N, Morii E, Watanabe M, Hibi T, Kanai T, Takehara T, Naka T. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J Crohns Colitis 2017;11:84-91. [PMID: 27466171 DOI: 10.1093/ecco-jcc/jjw132] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 11.2] [Reference Citation Analysis]
67 Smits LJT, Grelack A, Derikx LAAP, de Jong DJ, van Esch AAJ, Boshuizen RS, Drenth JPH, Hoentjen F. Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease. Dig Dis Sci 2017;62:3117-22. [PMID: 28667429 DOI: 10.1007/s10620-017-4661-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
68 Dalal RS, Klapproth J, Lichtenstein GR. Tricks of the Trade: Treating Your Patient with Moderate-to-Severe IBD. Clinical Gastroenterology 2017. [DOI: 10.1007/978-3-319-53763-4_10] [Reference Citation Analysis]
69 Bröms G, Granath F, Stephansson O, Kieler H. Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment. Scand J Gastroenterol 2016;51:1462-9. [PMID: 27739352 DOI: 10.1080/00365521.2016.1208269] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
70 Van Deen WK, van der Meulen-de Jong AE, Parekh NK, Kane E, Zand A, DiNicola CA, Hall L, Inserra EK, Choi JM, Ha CY, Esrailian E, van Oijen MG, Hommes DW. Development and Validation of an Inflammatory Bowel Diseases Monitoring Index for Use With Mobile Health Technologies. Clin Gastroenterol Hepatol 2016;14:1742-1750.e7. [PMID: 26598228 DOI: 10.1016/j.cgh.2015.10.035] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
71 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 1306] [Cited by in F6Publishing: 1116] [Article Influence: 186.6] [Reference Citation Analysis]
72 Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, Hoentjen F. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. J Crohns Colitis 2016;10:1287-93. [PMID: 27095751 DOI: 10.1093/ecco-jcc/jjw087] [Cited by in Crossref: 107] [Cited by in F6Publishing: 95] [Article Influence: 15.3] [Reference Citation Analysis]
73 Tedjo DI, Smolinska A, Savelkoul PH, Masclee AA, van Schooten FJ, Pierik MJ, Penders J, Jonkers DM. The fecal microbiota as a biomarker for disease activity in Crohn's disease. Sci Rep 2016;6:35216. [PMID: 27734914 DOI: 10.1038/srep35216] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
74 Pierdominici M, Maselli A, Varano B, Barbati C, Cesaro P, Spada C, Zullo A, Lorenzetti R, Rosati M, Rainaldi G, Limiti MR, Guidi L, Conti L, Gessani S. Linking estrogen receptor β expression with inflammatory bowel disease activity. Oncotarget 2015;6:40443-51. [PMID: 26497217 DOI: 10.18632/oncotarget.6217] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
75 Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol 2016;13:567-79. [PMID: 27580684 DOI: 10.1038/nrgastro.2016.128] [Cited by in Crossref: 128] [Cited by in F6Publishing: 112] [Article Influence: 18.3] [Reference Citation Analysis]
76 Taleban S, Stewart KO, Li DK, Singh P, Pardi DS, Sturgeon HC, Yajnik V, Xavier RJ, Ananthakrishnan AN, Khalili H. Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. Dig Dis Sci 2016;61:2627-35. [PMID: 27142671 DOI: 10.1007/s10620-016-4180-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
77 Hoekman DR, Diederen K, Koot BG, Tabbers MM, Kindermann A, Benninga MA. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease. Eur J Pediatr 2016;175:1335-42. [PMID: 27573259 DOI: 10.1007/s00431-016-2762-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
78 Ket SN, Palmer R, Travis S. Endoscopic Disease Activity in Inflammatory Bowel Disease. Curr Gastroenterol Rep 2015;17:50. [PMID: 26650939 DOI: 10.1007/s11894-015-0470-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
79 Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC. Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. Am J Gastroenterol 2016;111:541-51. [PMID: 27002800 DOI: 10.1038/ajg.2016.59] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 13.6] [Reference Citation Analysis]
80 Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, Loebstein R, Chowers Y, Eliakim R, Kopylov U, Ben-Horin S. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2016;14:550-557.e2. [PMID: 26538204 DOI: 10.1016/j.cgh.2015.10.025] [Cited by in Crossref: 249] [Cited by in F6Publishing: 142] [Article Influence: 35.6] [Reference Citation Analysis]
81 Serafin Z, Białecki M, Białecka A, Sconfienza LM, Kłopocka M. Contrast-enhanced Ultrasound for Detection of Crohn's Disease Activity: Systematic Review and Meta-analysis. J Crohns Colitis 2016;10:354-62. [PMID: 26507861 DOI: 10.1093/ecco-jcc/jjv196] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
82 Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther 2016;43:317-33. [PMID: 26607562 DOI: 10.1111/apt.13475] [Cited by in Crossref: 207] [Cited by in F6Publishing: 146] [Article Influence: 29.6] [Reference Citation Analysis]
83 van Deen WK, Hommes DW. Future Directions in Telemedicine Applications for Inflammatory Bowel Disease (IBD). Telemanagement of Inflammatory Bowel Disease 2016. [DOI: 10.1007/978-3-319-22285-1_11] [Reference Citation Analysis]
84 Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11246-11259 [PMID: 26523100 DOI: 10.3748/wjg.v21.i40.11246] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 96] [Article Influence: 12.0] [Reference Citation Analysis]
85 Boon GJ, Day AS, Mulder CJ, Gearry RB. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11469-11480 [PMID: 26523111 DOI: 10.3748/wjg.v21.i40.11469] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
86 Torki M, Gholamrezaei A, Mirbagher L, Danesh M, Kheiri S, Emami MH. Vitamin D Deficiency Associated with Disease Activity in Patients with Inflammatory Bowel Diseases. Dig Dis Sci 2015;60:3085-91. [PMID: 26031421 DOI: 10.1007/s10620-015-3727-4] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]